TriSalus Life Sciences has introduced the TriNav FLX Infusion System, a significant advancement in the company’s TriNav product portfolio. Building upon its proven Pressure-Enabled Drug Delivery™ (PEDD™) technology, the new system features an enhanced design that includes a longer, more flexible distal end. This innovation allows for greater trackability and precision when navigating through tortuous or complex vascular anatomy. Designed specifically for use in solid tumor treatment procedures, TriNav FLX aims to improve access and delivery in challenging cases where conventional catheters may fall short.

In terms of clinical usage, the TriNav FLX system demonstrated a 28% reduction in navigation force compared to the standard TriNav device in benchtop models. This improved maneuverability means that interventional radiologists can perform procedures more efficiently and with reduced physical strain. Its adaptability across a range of peripheral vessel sizes also allows clinicians to tailor the tool to patient-specific needs. Importantly, TriNav FLX qualifies for reimbursement under both HCPCS codes C8004 for simulation and C9797 for treatment, making it a practical option for both planning and delivery phases of radioembolization procedures.

The launch of TriNav FLX underscores TriSalus’ commitment to advancing interventional oncology by integrating precision engineering with therapeutic delivery. The system not only enhances the procedural experience for clinicians but also contributes to more consistent and targeted therapy for patients. As the demand for more refined tools in cancer care grows, TriNav FLX positions itself as a vital asset in improving clinical outcomes and expanding the accessibility of Pressure-Enabled Drug Delivery to broader patient populations.

MedTech Spectrum's Summary

The TriNav FLX Infusion System offers enhanced flexibility and trackability, enabling better navigation through complex vascular pathways for improved precision in treating solid tumors.

Its design reduces navigation force by 28%, supporting easier and more efficient procedures for interventional radiologists, while also being eligible for dual reimbursement codes for simulation and treatment.

TriNav FLX represents a major step forward in interventional oncology, improving both clinician experience and patient outcomes by expanding access to advanced Pressure-Enabled Drug Delivery technology.